Title : Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows
link : Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows
Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows
A new study has found use of remdesivir, the first medicine approved in the United States to treat COVID-19, may have resulted in longer hospital stays for infected patients.
A University of Iowa researcher led a study published this month that found the antiviral medication is not associated with improved survival among hospitalized patients 30 days after they were discharged.
The anti viral medication is NOT associated with improved survival rates.
Instead, data shows the drug regimen may have lengthened hospital stays — contradicting early clinical trials that stated patients would be discharged faster, opening more beds during critical surge periods of the pandemic.
“Whereas (remdesivir) was approved to give people out of the hospital quicker, it seemed to be related to them staying longer,” said Dr. Michael Ohl, professor of internal medicine with University of Iowa Health Care and a physician with the Iowa City Veterans Affairs Health Care System.
The research was published earlier this month in the medical journal, JAMA Network Open.
The study observed 2,344 adults hospitalized with COVID-19 in 123 VA hospitals nationwide, including 1,172 who received remdesivir and 1,172 who did not. These patients were admitted between May 1 and Oct. 8, 2020, during the period the drug had emergency use authorization by the U.S. Food and Drug Administration.
Patients who received remdesivir actually stayed in the hospital three days longer than those who did not, said Ohl, who led the research.
The additional length of stay is not a result of any side effects or health problems caused by the medication. Instead, it may be a result of federal recommendations that the drug is administered over a five- or 10-day course.
Data showed many COVID-19 patients who received remdesivir in the study were discharged exactly five days later, Ohl said, leading to the conclusion that providers were keeping patients admitted to complete the recommended course.
Was there a monetary incentive to keep these patients in hospital longer?
What ever the case the Remdesvir was " not associated with improved survival among hospitalized patients 30 days after they were discharged.
I guess Remdsevir and the covid jabs share common traits? Both are ineffective. Heavily promoted. And very profitable for pharmaceutical manufacturers.
Related:
- Among Fully Vaccinated, Breakthrough Covid-19 Infections Are More Common Than Previously Thought: Does It Matter?
-
Covid Cases Among Double Vaccinated Are Rising- But That Doesn't Mean the Vaccines Are Not Working?
From earlier:
Thus Article Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows
You are now reading the article Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows with the link address https://janggalnews.blogspot.com/2021/07/remdesivir-treatment-plan-kept-covid-19.html
0 Response to "Remdesivir treatment plan kept COVID-19 patients hospitalized longer, University of Iowa research shows"
Post a Comment